Regional distribution of synaptic markers and APP correlate with distinct clinicopathological features in sporadic and familial Alzheimer's disease.

Recent studies suggest that subcortical structures, including striatum, are vulnerable to amyloid-β accumulation and other neuropathological features in familial Alzheimer's disease due to autosomal dominant mutations. We explored differences between familial and sporadic Alzheimer's disease that might shed light on their respective pathogenic mechanisms. To this end, we analysed 12 brain regions, including neocortical, limbic and subcortical areas, from post-mortem brains of familial Alzheimer's disease (n = 10; age at death: 50.0 ± 8.6 years) with mutations in amyloid precursor protein (APP) or presenilin 1 (PSEN1), sporadic Alzheimer's disease (n = 19; age at death: 84.7 ± 7.8 years), neurologically normal elderly without amyloid-β accumulation (normal ageing; n = 13, age at death: 82.9 ± 10.8 years) and neurologically normal elderly with extensive cortical amyloid-β deposits (pathological ageing; n = 15; age at death: 92.7 ± 5.9 years). The levels of amyloid-β₄₀, amyloid-β₄₂, APP, apolipoprotein E, the synaptic marker PSD95 (now known as DLG4), the astrocyte marker GFAP, other molecules related to amyloid-β metabolism, and tau were determined by enzyme-linked immunosorbent assays. We observed that familial Alzheimer's disease had disproportionate amyloid-β₄₂ accumulation in subcortical areas compared with sporadic Alzheimer's disease, whereas sporadic Alzheimer's disease had disproportionate amyloid-β₄₂ accumulation in cortical areas compared to familial Alzheimer's disease. Compared with normal ageing, the levels of several proteins involved in amyloid-β metabolism were significantly altered in both sporadic and familial Alzheimer's disease; however, such changes were not present in pathological ageing. Among molecules related to amyloid-β metabolism, the regional distribution of PSD95 strongly correlated with the regional pattern of amyloid-β₄₂ accumulation in sporadic Alzheimer's disease and pathological ageing, whereas the regional distribution of APP as well as β-C-terminal fragment of APP were strongly associated with the regional pattern of amyloid-β₄₂ accumulation in familial Alzheimer's disease. Apolipoprotein E and GFAP showed negative regional association with amyloid-β (especially amyloid-β₄₀) accumulation in both sporadic and familial Alzheimer's disease. Familial Alzheimer's disease had greater striatal tau pathology than sporadic Alzheimer's disease. In a retrospective medical record review, atypical signs and symptoms were more frequent in familial Alzheimer's disease compared with sporadic Alzheimer's disease. These results suggest that disproportionate amyloid-β₄₂ accumulation in cortical areas in sporadic Alzheimer's disease may be mediated by synaptic processes, whereas disproportionate amyloid-β₄₂ accumulation in subcortical areas in familial Alzheimer's disease may be driven by APP and its processing. Region-specific amyloid-β₄₂ accumulation might account for differences in the relative amounts of tau pathology and clinical symptoms in familial and sporadic Alzheimer's disease.

[1]  N. Sahara,et al.  Characteristics of Tau Oligomers , 2013, Front. Neurol..

[2]  Michel Goedert,et al.  Tau pathology and neurodegeneration , 2013, The Lancet Neurology.

[3]  G. Bu,et al.  What can we learn from regional vulnerability to amyloid-b accumulation in nondemented individuals? , 2013 .

[4]  Nick C Fox,et al.  Magnetic resonance imaging evidence for presymptomatic change in thalamus and caudate in familial Alzheimer’s disease , 2013, Brain : a journal of neurology.

[5]  W. Thies,et al.  2013 Alzheimer's disease facts and figures , 2013, Alzheimer's & Dementia.

[6]  C. Jack,et al.  Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers , 2013, The Lancet Neurology.

[7]  R. Petersen,et al.  Brain regional correlation of amyloid-β with synapses and apolipoprotein E in non-demented individuals: potential mechanisms underlying regional vulnerability to amyloid-β accumulation , 2013, Acta Neuropathologica.

[8]  P. Thompson,et al.  Regional brain volume differences in symptomatic and presymptomatic carriers of familial Alzheimer's disease mutations , 2012, Journal of Neurology, Neurosurgery & Psychiatry.

[9]  Robert Lalonde,et al.  Brain regions and genes affecting myoclonus in animals , 2012, Neuroscience Research.

[10]  Ranjan Duara,et al.  Neuropathologically defined subtypes of Alzheimer’s disease differ significantly from neurofibrillary tangle-predominant dementia , 2012, Acta Neuropathologica.

[11]  Dennis W Dickson,et al.  C9ORF72 repeat expansions and other FTD gene mutations in a clinical AD patient series from Mayo Clinic. , 2012, American journal of neurodegenerative disease.

[12]  V. Caso,et al.  Caudate infarcts and hemorrhages. , 2012, Frontiers of neurology and neuroscience.

[13]  R. Huganir,et al.  Arc/Arg3.1 Regulates an Endosomal Pathway Essential for Activity-Dependent β-Amyloid Generation , 2011, Cell.

[14]  B. Strooper,et al.  The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics , 2011, Nature Reviews Drug Discovery.

[15]  Jee Hoon Roh,et al.  Neuronal activity regulates the regional vulnerability to amyloid-β deposition , 2011, Nature Neuroscience.

[16]  G. Small,et al.  Biochemical, neuropathological, and neuroimaging characteristics of early-onset Alzheimer's disease due to a novel PSEN1 mutation , 2011, Neuroscience Letters.

[17]  Nick C Fox,et al.  Carbon-11-Pittsburgh compound B positron emission tomography imaging of amyloid deposition in presenilin 1 mutation carriers. , 2011, Brain : a journal of neurology.

[18]  John X. Morris,et al.  Spatial correlation between brain aerobic glycolysis and amyloid-β (Aβ) deposition , 2010, Proceedings of the National Academy of Sciences.

[19]  D. Dickson,et al.  Massive gliosis induced by interleukin‐6 suppresses Aβ deposition in vivo: evidence against inflammation as a driving force for amyloid deposition , 2010, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[20]  Masanori Nakagawa,et al.  High striatal amyloid beta-peptide deposition across different autosomal Alzheimer disease mutation types. , 2009, Archives of neurology.

[21]  Guojun Bu,et al.  Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy , 2009, Nature Reviews Neuroscience.

[22]  Kristina D. Micheva,et al.  Oligomeric amyloid β associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques , 2009, Proceedings of the National Academy of Sciences.

[23]  M. Doran,et al.  Genotype-phenotype relationships of presenilin-1 mutations in Alzheimer's disease: an update. , 2008, Journal of Alzheimer's disease : JAD.

[24]  Scott A. Small,et al.  Linking Aβ and Tau in Late-Onset Alzheimer's Disease: A Dual Pathway Hypothesis , 2008, Neuron.

[25]  E. Koo,et al.  Amyloid Precursor Protein Trafficking, Processing, and Function* , 2008, Journal of Biological Chemistry.

[26]  A. Paetau,et al.  PET amyloid ligand [11C]PIB uptake shows predominantly striatal increase in variant Alzheimer's disease. , 2008, Brain : a journal of neurology.

[27]  S. Aalto,et al.  Carbon 11-labeled pittsburgh compound B positron emission tomographic amyloid imaging in patients with APP locus duplication. , 2008, Archives of neurology.

[28]  D. Dickson,et al.  Differential incorporation of tau isoforms in Alzheimer's disease. , 2008, Journal of Alzheimer's disease : JAD.

[29]  Florence Pasquier,et al.  Phenotype associated with APP duplication in five families. , 2006, Brain : a journal of neurology.

[30]  Keith A. Johnson,et al.  P2-366 Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees , 2006, Alzheimer's & Dementia.

[31]  C. van Broeckhoven,et al.  Mean age‐of‐onset of familial alzheimer disease caused by presenilin mutations correlates with both increased Aβ42 and decreased Aβ40 , 2006, Human mutation.

[32]  D. Campion,et al.  APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy , 2006, Nature Genetics.

[33]  M. Doran,et al.  Clinical phenotypic heterogeneity of Alzheimer's disease associated with mutations of the presenilin–1 gene , 2006, Journal of Neurology.

[34]  Steven Mennerick,et al.  Synaptic Activity Regulates Interstitial Fluid Amyloid-β Levels In Vivo , 2005, Neuron.

[35]  Benjamin J. Shannon,et al.  Molecular, Structural, and Functional Characterization of Alzheimer's Disease: Evidence for a Relationship between Default Activity, Amyloid, and Memory , 2005, The Journal of Neuroscience.

[36]  J. Schröder,et al.  Mean age of onset in familial Alzheimer's disease is determined by amyloid beta 42 , 2005, Neurobiology of Aging.

[37]  David M Holtzman,et al.  Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo. , 2005, Neuron.

[38]  T. Chase.  Striatal plasticity and extrapyramidal motor dysfunction. , 2004, Parkinsonism & related disorders.

[39]  S. Paul,et al.  Apolipoprotein E promotes astrocyte colocalization and degradation of deposited amyloid-β peptides , 2004, Nature Medicine.

[40]  P. Mcgeer,et al.  Specificity of mechanisms for plaque removal after Aβ immunotherapy for Alzheimer disease , 2004, Nature Medicine.

[41]  S. Hirai,et al.  Presence of apolipoprotein E on extracellular neurofibrillary tangles and on meningeal blood vessels precedes the Alzheimer β-amyloid deposition , 2004, Acta Neuropathologica.

[42]  H. Braak,et al.  Neuropathological stageing of Alzheimer-related changes , 2004, Acta Neuropathologica.

[43]  L. Vercueil,et al.  Seizures and the basal ganglia: a review of the clinical data. , 2002, Epileptic disorders : international epilepsy journal with videotape.

[44]  P. Greengard,et al.  Intraneuronal Alzheimer abeta42 accumulates in multivesicular bodies and is associated with synaptic pathology. , 2002, The American journal of pathology.

[45]  H. Braak,et al.  Phases of Aβ-deposition in the human brain and its relevance for the development of AD , 2002, Neurology.

[46]  K. Komatsuzaki,et al.  Immunohistochemical detection of apolipoprotein E within prion-associated lesions in squirrel monkey brains , 2000, Acta Neuropathologica.

[47]  A. Fagan,et al.  Apolipoprotein E facilitates neuritic and cerebrovascular plaque formation in an Alzheimer's disease model , 2000, Annals of neurology.

[48]  K. Blennow,et al.  A Quantitative and Immunohistochemical Study on Apolipoprotein E in Brain Tissue in Alzheimer’s Disease , 1999, Dementia and Geriatric Cognitive Disorders.

[49]  J. Vickers,et al.  Relationship between apolipoprotein E and the amyloid deposits and dystrophic neurites of Alzheimer's disease , 1997, Neuropathology and applied neurobiology.

[50]  H. Arai,et al.  Distribution of apolipoprotein E in senile plaques in brains with Alzheimer's disease: investigation with the confocal laser scan microscope , 1997, Brain Research.

[51]  D. Mann,et al.  Preferential deposition of amyloid β protein (Aβ) in the form Aβ 40 in Alzheimer's disease is associated with a gene dosage effect of the apolipoprotein E E4 allele , 1997, Neuroscience Letters.

[52]  D. Mann,et al.  Preferential deposition of amyloid beta protein (Abeta) in the form Abeta40 in Alzheimer's disease is associated with a gene dosage effect of the apolipoprotein E E4 allele. , 1997, Neuroscience letters.

[53]  S. Tsuji,et al.  Pick’s disease: selective occurrence of apolipoprotein E-immunoreactive Pick bodies in the limbic system , 1997, Acta Neuropathologica.

[54]  J. Hardy,et al.  Increased amyloid-β42(43) in brains of mice expressing mutant presenilin 1 , 1996, Nature.

[55]  G. Schellenberg,et al.  Secreted amyloid β–protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease , 1996, Nature Medicine.

[56]  M. Gearing,et al.  Aβ‐peptide length aid apolipoprotein E genotype in Alzheimer's disease , 1996 .

[57]  J. Hardy,et al.  Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. , 1996, Nature medicine.

[58]  M. Gearing,et al.  Abeta-peptide length and apolipoprotein E genotype in Alzheimer's disease. , 1996, Annals of Neurology.

[59]  T. Iwatsubo,et al.  Visualization of Aβ42(43) and Aβ40 in senile plaques with end-specific Aβ monoclonals: Evidence that an initially deposited species is Aβ42(43) , 1994, Neuron.

[60]  T. Iwatsubo,et al.  Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43). , 1994, Neuron.

[61]  P. Lantos,et al.  Alzheimer's Disease Families with Amyloid Precursor Protein Mutations a , 1993, Annals of the New York Academy of Sciences.

[62]  M. Pericak-Vance,et al.  Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[63]  D. Selkoe,et al.  Mutation of the β-amyloid precursor protein in familial Alzheimer's disease increases β-protein production , 1992, Nature.

[64]  P. Mcgeer,et al.  Localization of amyloid precursor protein in selective postsynaptic densities of rat cortical neurons , 1992, Brain Research.

[65]  Peter Davies,et al.  Identification of normal and pathological aging in prospectively studied nondemented elderly humans , 1992, Neurobiology of Aging.

[66]  D. Selkoe,et al.  Mutation of the beta-amyloid precursor protein in familial Alzheimer's disease increases beta-protein production. , 1992, Nature.

[67]  E. Otomo,et al.  Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer's disease and kuru plaque amyloid in Creutzfeldt-Jakob disease , 1991, Brain Research.